Compare UVE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | MDXG |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 530.2M |
| IPO Year | 1996 | 2007 |
| Metric | UVE | MDXG |
|---|---|---|
| Price | $36.91 | $3.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $9.00 |
| AVG Volume (30 Days) | 156.4K | ★ 1.5M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | 14.29 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $1,603,915,000.00 | $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $13.02 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | 5.48 | ★ 19.99 |
| 52 Week Low | $21.96 | $3.03 |
| 52 Week High | $41.96 | $7.99 |
| Indicator | UVE | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 51.81 |
| Support Level | $32.51 | $3.45 |
| Resistance Level | $41.32 | $3.80 |
| Average True Range (ATR) | 1.16 | 0.12 |
| MACD | -0.45 | 0.03 |
| Stochastic Oscillator | 1.98 | 65.71 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.